InMed Pharmaceuticals Inc.INMEarnings & Financial Report
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
Revenue
$1.3M
Gross Profit
$493.4K
Operating Profit
$-1.7M
Net Profit
$-1.7M
Gross Margin
39.0%
Operating Margin
-132.7%
Net Margin
-132.7%
YoY Growth
40.2%
EPS
$-2.71
InMed Pharmaceuticals Inc. Q1 FY2025 Financial Summary
InMed Pharmaceuticals Inc. reported revenue of $1.3M (up 40.2% YoY) for Q1 FY2025, with a net profit of $-1.7M (up 33.9% YoY) (-132.7% margin). Cost of goods sold was $771.2K, operating expenses totaled $2.2M.
Key Financial Metrics
| Total Revenue | $1.3M |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | 39.0% |
| Operating Margin | -132.7% |
| Report Period | Q1 FY2025 |
InMed Pharmaceuticals Inc. Annual Revenue by Year
InMed Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $4.9M |
| 2024 | $4.6M |
| 2023 | $4.1M |
InMed Pharmaceuticals Inc. Quarterly Revenue & Net Profit History
InMed Pharmaceuticals Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $820.2K | -26.2% | $-2.0M | -247.3% |
| Q1 FY2026 | $1.1M | -11.4% | $-1.7M | -154.2% |
| Q4 FY2025 | $1.3M | +1.7% | $-1.8M | -137.1% |
| Q3 FY2025 | $1.3M | +7.6% | $-2.1M | -168.1% |
| Q2 FY2025 | $1.1M | -10.4% | $-2.6M | -231.6% |
| Q1 FY2025 | $1.3M | +40.2% | $-1.7M | -132.7% |
| Q4 FY2024 | $1.3M | -44.5% | $-1.9M | -151.0% |
| Q3 FY2024 | $1.2M | +13.4% | $-1.7M | -146.9% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.3M | $1.3M | $1.1M | $1.3M | $1.3M | $1.1M | $820188 |
| YoY Growth | 13.4% | -44.5% | 40.2% | -10.4% | 7.6% | 1.7% | -11.4% | -26.2% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | $11.8M | $10.5M | $8.5M | $9.3M | $15.6M | $13.4M | $11.2M |
| Liabilities | N/A | $2.6M | $2.1M | $2.3M | $2.3M | $2.1M | $1.8M | $1.6M |
| Equity | $11.1M | $9.2M | $8.4M | $6.2M | $7.0M | $13.4M | $11.6M | $9.6M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.9M | $-1.0M | $-1.8M | $-2.5M | $-1.7M | $-1.8M | $-1.6M | $-2.4M |